PMID- 17150109
OWN - NLM
STAT- MEDLINE
DCOM- 20070108
LR  - 20181113
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 6
DP  - 2006 Dec 6
TI  - A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular 
      carcinoma.
PG  - 278
AB  - BACKGROUND: Several studies showed that gain-of-function somatic mutations 
      affecting the catalytic domain of EGFR in non-small cell lung carcinomas were 
      associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase 
      inhibitors. In addition, 4% of non-small cell lung carcinomas were shown to have 
      ERBB2 mutations in the kinase domain. In our study, we sought to determine if 
      similar respective gain-of-function EGFR and ERBB2 mutations were present in 
      hepatoma and/or biliary cancers. METHODS: We extracted genomic DNA from 40 
      hepatoma (18) and biliary cancers (22) samples, and 44 adenocarcinomas of the 
      lung, this latter as a positive control for mutation detection. We subjected 
      those samples to PCR-based semi-automated double stranded nucleotide sequencing 
      targeting exons 18-21 of EGFR and ERBB2. All samples were tested against matched 
      normal DNA. RESULTS: We found 11% of hepatoma, but no biliary cancers, harbored a 
      novel ERBB2 H878Y mutation in the activating domain. CONCLUSION: These newly 
      described mutations may play a role in predicting response to EGFR-targeted 
      therapy in hepatoma and their role should be explored in prospective studies.
FAU - Bekaii-Saab, Tanios
AU  - Bekaii-Saab T
AD  - Division of Hematology and Oncology, Department of Internal Medicine, 
      Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA. 
      Tanios.Bekaii-Saab@osumc.edu
FAU - Williams, Nita
AU  - Williams N
FAU - Plass, Christoph
AU  - Plass C
FAU - Calero, Miguel Villalona
AU  - Calero MV
FAU - Eng, Charis
AU  - Eng C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20061206
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Carcinoma, Hepatocellular/*enzymology/*genetics
MH  - Genes, erbB-2/genetics
MH  - Humans
MH  - Liver Neoplasms/*enzymology/*genetics
MH  - Mutation, Missense/*genetics
MH  - Protein-Tyrosine Kinases/*genetics
MH  - Receptor, ErbB-2/*genetics/metabolism
PMC - PMC1712353
EDAT- 2006/12/08 09:00
MHDA- 2007/01/09 09:00
PMCR- 2006/12/06
CRDT- 2006/12/08 09:00
PHST- 2006/08/24 00:00 [received]
PHST- 2006/12/06 00:00 [accepted]
PHST- 2006/12/08 09:00 [pubmed]
PHST- 2007/01/09 09:00 [medline]
PHST- 2006/12/08 09:00 [entrez]
PHST- 2006/12/06 00:00 [pmc-release]
AID - 1471-2407-6-278 [pii]
AID - 10.1186/1471-2407-6-278 [doi]
PST - epublish
SO  - BMC Cancer. 2006 Dec 6;6:278. doi: 10.1186/1471-2407-6-278.